| Literature DB >> 31062259 |
Matisyahu Shulman1,2, Jonathan M Wai3,4, Edward V Nunes3,4.
Abstract
Opioid use disorder affects over 26 million individuals worldwide. There are currently three World Health Organization-recommended and US Food and Drug Administration-approved medication treatments for opioid use disorder: the full opioid agonist methadone, the opioid partial agonist buprenorphine, and the opioid receptor antagonist naltrexone. We provide a review of the use of buprenorphine for the treatment of opioid use disorder and discuss the barriers, challenges, risks, and efficacy of buprenorphine treatment vs. other treatments. Although evidence from numerous studies has shown buprenorphine to be effective for the treatment of opioid use disorder, a majority of patients with opioid use disorder do not receive buprenorphine, or any other medical treatment. We review the different formulations of buprenorphine, including newer long-acting injectable formulations that may decrease the risk of diversion and improve adherence.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31062259 PMCID： PMC6585403 DOI： 10.1007/s40263-019-00637-z
Source DB: PubMed Journal: CNS Drugs ISSN： 1172-7047 Impact factor: 5.749